On October 3, 2023, Hemostemix Inc. closed the transaction. The company issued 2,669,875 units at an issue price of CAD 0.12 for the gross proceeds of CAD 320,385. The company has paid eligible finders aggregate fees of CAD 5,750.40 in cash and issued 47,920 finder options to purchase common shares, at an exercise price of CAD 0.12 per common share within 24 months from the closing of the offering. The board of directors has authorized the issuance of 2,375,000 stock options at CAD 7 each, to directors, officers and consultants of the company.

The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement. The transaction included participation from 12 placees including pro group involvement of one pro group for 100,000.